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ABSTRACT Two of the major classes of antifungal drugs in clinical use target er-
gosterol biosynthesis. Despite its importance, our understanding of the transcrip-
tional regulation of ergosterol biosynthesis genes in pathogenic fungi is essentially
limited to the role of hypoxia and sterol-stress-induced transcription factors such
as Upc2 and Upc2A as well as homologs of sterol response element binding (SREB)
factors. To identify additional regulators of ergosterol biosynthesis in Candida glab-
rata, an important human fungal pathogen with reduced susceptibility to ergos-
terol biosynthesis inhibitors relative to other Candida spp., we used a serial passag-
ing strategy to isolate suppressors of the fluconazole hypersusceptibility of a
upc2AD deletion mutant. This led to the identification of loss-of-function mutations
in two genes: ROX1, the homolog of a hypoxia gene transcriptional suppressor in
Saccharomyces cerevisiae, and CST6, a transcription factor that is involved in the
regulation of carbon dioxide response in C. glabrata. Here, we describe a detailed
analysis of the genetic interaction of ROX1 and UPC2A. In the presence of flucona-
zole, loss of Rox1 function restores ERG11 expression to the upc2AD mutant and
inhibits the expression of ERG3 and ERG6, leading to increased levels of ergosterol
and decreased levels of the toxic sterol 14a methyl-ergosta-8,24(28)-dien-3b , 6a-
diol, relative to the upc2AD mutant. Our observations establish that Rox1 is a nega-
tive regulator of ERG gene biosynthesis and indicate that a least one additional
positive transcriptional regulator of ERG gene biosynthesis must be present in C.
glabrata.
IMPORTANCE Candida glabrata is one of the most important human fungal patho-
gens and has reduced susceptibility to azole-class inhibitors of ergosterol biosyn-
thesis. Although ergosterol is the target of two of the three classes of antifungal
drugs, relatively little is known about the regulation of this critical cellular path-
way. Sterols are both essential components of the eukaryotic plasma membrane
and potential toxins; therefore, sterol homeostasis is critical for cell function. Here,
we identified two new negative regulators in C. glabrata of ergosterol (ERG) bio-
synthesis gene expression. Our results also indicate that in addition to Upc2A, the
only known activator of ERG genes, additional positive regulators of this pathway
must exist.
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C andida species are a very common cause of human fungal infections. Candidiasisencompasses infections of mucosal and epidermal tissues such as oropharyngeal
candidiasis and vulvovaginal candidiasis as well as invasive infections of deep organs
and the bloodstream (1). Mucosal infections affect both immunocompetent and immu-
nocompromised people while invasive infections primarily affect critically ill patients or
those with altered immune function. Although Candida albicans is the most prevalent
infecting species, the so-called non-albicans Candida spp., such as C. glabrata, C. para-
psilosis (2) and, most recently, C. auris, have emerged as clinically significant causes of
candidiasis (3). Of these, C. glabrata is the second most common cause of candidiasis
in most clinical case series of invasive infections (1, 2).
One of the most important characteristics that distinguishes C. glabrata from C. albi-
cans is that C. glabrata is less susceptible to azole antifungal drugs and has the highest
rate of resistance to echinocandins; thus, C. glabrata has reduced susceptibility to two
of the three classes of drugs currently used to treat invasive fungal infections (4). The
rate of azole and echinocandin resistance varies significantly by institution (5). For
example, some institutions report almost no resistance while others have fluconazole
resistance rates as high as 18%. In contrast, the rates of C. albicans azole resistance
remain uniformly quite low. Genomic sequences of azole-resistant C. albicans isolates
indicate that mutations in multiple genes can lead to resistance, including gain-of-
function mutations in transcription factors regulating drug efflux pump expression,
mutations in the azole target ERG11, and gain-of-function mutations in UPC2, a tran-
scription factor that regulates the expression of ergosterol biosynthesis genes during
periods of sterol depletion (6). Curiously, mutations associated with azole resistance in
C. glabrata clinical isolates are essentially limited to gain-of-function alleles in PDR1,
the transcription factor that regulates efflux pump expression, suggesting that these
two species adapt to azole-induced sterol depletion in very different ways (7, 8).
Although gain-of-function mutations in the C. glabrata ortholog of C. albicans Upc2,
UPC2A, have not been isolated in fluconazole-resistant C. glabrata clinical isolates,
Whaley et al. showed that UPC2A was essential for fluconazole resistance in PDR1 gain-
of-function mutants (9). In the absence of sterol stress such as hypoxia or azole expo-
sure, UPC2A has a modest effect on ergosterol gene (ERG) expression (9–11); however,
under these inducers of sterol stress, upc2AD mutants show a dramatic reduction in fit-
ness (9, 10). Previous studies in C. glabrata indicate that Upc2A regulates genes
involved in the uptake of exogenous sterols during hypoxic growth (11). However, little
is known about how UPC2A interacts with other genes involved in ergosterol biosyn-
thesis or the cellular response to sterol depletion. In Saccharomyces cerevisiae, the
Upc2A homolog ScUpc2 functions with ScEcm22 to regulate sterol biosynthesis (12).
The upc2D ecm22D double mutant is viable but hypersusceptible to inhibitors of the
ergosterol pathway and resistant to amphotericin B (12). In C. glabrata, Upc2B is ho-
mologous to Upc2A but upc2BD mutants do not show increased susceptibility to fluco-
nazole or decreased growth under hypoxic conditions (10). These observations suggest
that the transcriptional regulation of the ergosterol pathway in C. glabrata is distinct
from that in the model yeast S. cerevisiae.
More generally, the regulation of ERG gene expression in fungal pathogens is
remarkably understudied given the importance of the ergosterol biosynthesis pathway
to the treatment of fungal infections (13); two of the three main therapies, azoles and
polyenes, target ergosterol. To date, the main focus of this area of research has been
on factors related to mammalian sterol response element binding (SREB) proteins or
the Zinc(2)-Cys(6) factors such as Upc2A that function similarly to SREB factors but
have no sequence homology to those proteins (14). Furthermore, if we consider the
fact that these factors are not essential and have little effect on ergosterol levels or
growth in the absence of sterol stress, then additional pathways and factors must regu-
late the expression of ERG genes.
To identify additional regulators of the ERG pathway under sterol stress, we took
advantage of the fact that deletion of UPC2A prevents increased efflux pump
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expression from causing azole resistance and designed a laboratory evolution experi-
ment for the isolation of suppressors of upc2AD fluconazole hypersusceptibility (9). In
wild-type cells, an experimental laboratory evolution approach in the presence of flu-
conazole would be expected to lead to gain-of-function mutants in Pdr1, the transcrip-
tion factor (TF) that regulates the expression of efflux pumps CDR1/2. We hypothesized
that the presence of a upc2AD mutation would prevent the emergence of PDR1 gain-
of-function mutations and allow us to identify either gain-of-function mutants in other
positive regulators of ERG gene expression or, alternatively, loss-of-function mutants in
negative regulators.
As we describe below, this laboratory evolution strategy led to the isolation of loss-
of-function mutations in two transcription regulators: ROX1 and CST6. ROX1 is homolo-
gous to a repressor of hypoxia genes in S. cerevisiae (15), while CST6 is a homolog of an
S. cerevisiae and a C. albicans (Rca1) transcriptional regulator of carbonic anhydrase
expression (16). In this report, we focused our characterization on the transcriptional
and biochemical changes that mediate the suppression of upc2AD fluconazole hyper-
susceptibility by ROX1 loss-of-function mutations; a detailed analysis of the interaction
of CST6 with UPC2A awaits additional work.
RESULTS
Experimental laboratory evolution generates suppressors of upc2AD fluconazole
hypersusceptibility. The general strategy for our experimental laboratory evolution
experiment is outlined in Fig. 1A. First, we constructed a upc2AD mutant in the His-BG2
genetic background (17) using a recyclable dominant selectable marker system
recently reported by members of our team (18). Three founder colonies were selected,
and 88 lineages from each were inoculated into a microtiter plate containing yeast-
peptone-dextrose (YPD) medium supplemented with fluconazole at 1/8 MIC (0.25 mg/
ml) of the parental strains (Fig. 1). The cultures were grown to stationary phase and
then passaged to a 2-fold-higher concentration of fluconazole until a final concentra-
tion of 64 mg/ml (32 MIC) was reached. All but 20 lineages went extinct before reach-
ing a fluconazole concentration of 64 mg/ml. The contents of wells that grew at 64 mg/
ml were plated on YPD as well as on synthetic medium lacking histidine to eliminate
possible environmental contaminants. Inspection of the YPD plates indicated that the
majority of wells contained heterogenous mixtures of small colonies and rarer large
colonies, although some wells had large colonies only (Fig. 1B).
We purified both types of colonies by serially passaging on YPD plates without flu-
conazole three times. The small-colony isolates retained this colony morphology in the
absence of selective pressure. These small colonies also grew poorly on glucose rela-
tive to the parental upc2AD strains but were much more fit than the parental upc2AD
strains in the presence of fluconazole (Fig. 1C). The small colony size and poor growth
on glucose strongly suggested that these strains might have mitochondrial defects
(19). Consistent with that hypothesis, the small-colony isolates were unable to grow on
glycerol plates and showed decreased mitochondrial DNA staining (data not shown),
consistent with petite isolates. Previous work has shown that petite C. glabrata strains
as well as those with other mitochondrial defects have increased Pdr1 activity, elevated
expression of the Cdr1 efflux pump, and reduced fluconazole susceptibility (19).
From the large-colony isolates, 11 retained decreased fluconazole susceptibility rel-
ative to the parental upc2AD strains after serial passaging on YPD plates (Fig. 1D). The
growth curves for two representative resistant isolates are provided in Fig. S1 in the
supplemental material, further confirming the resistance of the strains to fluconazole
relative to the upc2AD strain. As discussed above, the most common mechanism of flu-
conazole resistance is Pdr1 gain-of-function mutations that lead to increased expres-
sion of Cdr1, a putative fluconazole efflux pump (7, 8). To determine if any of the 11
large-colony isolates had increased Cdr1 expression, we analyzed the protein levels of
Cdr1 protein in the suppressor strains by Western blotting (Fig. 1E). Of the 11 suppres-
sors, only two strains showed evidence of increased Cdr1 expression relative to the pa-
rental strain: the petite strain and P1A1b, a nonpetite mutant. Thus, the decreased
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fluconazole susceptibility for the majority (10/11) of the suppressor mutants cannot be
explained by Pdr1-mediated efflux pump activation. As noted above, petite strains of
C. glabrata activate Pdr1, and these data further support the assignment of these
strains as petite (19). Previous experiments in a clinical C. glabrata isolate indicated
that upc2AD strongly reduced the effect of Pdr1 gain-of-function mutations on
FIG 1 Experimental laboratory evolution identifies suppressors of upc2AD fluconazole hypersusceptibility. (A) Schematic of selection
strategy. The parental strains were independent isolates of a upc2AD mutant generated in the BG2 background. The evolved isolates
were coded as follows: P, parent 1, 2, or 3; column of well A to H; row 1 to 12; and a or b isolate, e.g., P1E1a. (B) Representative
plates inoculated with the contents of wells with growth at 64 mg/ml of fluconazole. The red arrow indicates a representative large-
colony isolate, and the black arrow indicates a representative petite-colony isolate. (C) Spot dilution assays of representative petite-
colony isolates on YPD and YPD 1 40 mg/ml fluconazole. (D) Spot dilution assays of representative large-colony isolates on YPD and
YPD 1 40 mg/ml fluconazole. (E) Western blot analysis of representative large-colony and petite isolates blotted using a polyclonal
anti-Cdr1 antibody after growth in YPD to log phase. The blot is representative of two biological replicates which showed the same
pattern. The parental strains noted as P1 and P2 are upc2AD derivatives of BG2, which is noted as wild type in the blot. The P1-petite
is a representative petite strain isolated from the P1 parent. An antitubulin antibody blot was used as a loading control.
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fluconazole susceptibility (9). Our observations, however, indicate that under some cir-
cumstances Pdr1 activation can lead to Upc2A-independent reduction in fluconazole
susceptibility but that upc2AD mutation largely prevents the emergence of PDR1 gain-
of-function mutations as a mechanism of fluconazole resistance.
Genomic sequencing identifies putative loss-of-function mutations in ROX1 and
CST6 in the majority of upc2AD fluconazole suppressor strains. The parental upc2AD
founder strains as well as 12 suppressor strains were resequenced. Following analysis
using the Lasergene suite of software, 11 strains were found to contain mutations
within coding regions (Fig. 2A). Of these 11, 6 contained either frameshift or nonsense
mutations that would lead to loss of function in CAGL0I05170g (17, 20), a homolog of
S. cerevisiae transcription factor ScCST6 (C. glabrata gene and protein names do not
have prefix modifiers here while C. albicans and S. cerevisiae genes and protein names
do have species prefixes). Four strains contained similar types of loss-of-function muta-
tions in CAGL0D05434g, homologous to the S. cerevisiae high-mobility group (HMG)
transcriptional repressor ROX1 (15, 17). One strain contained a nonsense codon in
CAGL0D03828g, an uncharacterized homolog of the S. cerevisiae mediator component,
MED6; this is predicted to be an essential protein and was not pursued further. One
rox1 and one cst6 mutant strain also had additional nonsynonymous polymorphism in
the cell surface adhesion gene PWP3. Finally, a cst6 mutant strain also had a nonsynon-
ymous polymorphism in the putative glucose transporter HXT4.
In S. cerevisiae, ScCst6 has been shown to regulate the expression of carbonic anhy-
drase (NCE103), and deletion mutants of CST6 have similarly been shown to play a
modest role in the expression of NCE103 and CO2 sensing in C. glabrata (21). In C. albi-
cans, CaRCA1 is the homolog of ScCST6 and CST6. CaRCA1 plays a role in NCE102
expression (21) but also appears to affect ergosterol biosynthesis as evidenced by the
observations that Carca1DD mutants have decreased susceptibility to fluconazole and
reduced levels of ergosterol relative to the wild type (WT) (22). A library of C. glabrata
deletion mutants contains a cst6D strain, but it was not reported to have altered sus-
ceptibility to fluconazole. The putative CST6 loss-of-function mutations identified in
FIG 2 Loss-of-function mutations in ROX1 and CST6 are present in the upc2AD fluconazole-
suppressor strains. (A) The table indicates the code for the individual isolate and the coding region
mutation identified in that isolate. Isolates containing CST6 mutations are indicated by blue-shaded
rows, and those containing ROX1 mutations are indicated by boldface on a gray background.
Additional mutations are in lightface on gray backgrounds without boldface. (B) Location of
mutations in CST6. (C) Location of mutations in ROX1. aa, amino acids.
C. glabrata Rox1 Negatively Regulates ERG Expression














































these strains are frameshift or nonsense mutations within the N-terminal third of the
protein, well short of the basic leucine zipper (bZip) DNA binding domain (Fig. 2B).
In S. cerevisiae, Rox1 is a well-studied HMG repressor of hypoxia-related genes includ-
ing ergosterol biosynthesis genes. Indeed, ScRox1 functions to repress some genes that
are activated by ScUpc2 and its ortholog ScEcm33 in response to either ergosterol deple-
tion or reduced oxygen availability (23). For example, previous work from the Edlind lab
has shown that deletion of ScROX1 decreases the susceptibility of S. cerevisiae to azole
antifungals 4- to 10-fold and increases the expression of ERG genes (24). However, the
role of ROX1 in C. glabrata has not been investigated previously besides as part of the
large-scale library screening (17). This screen found that the rox1D mutant was more sus-
ceptible to amphotericin but similar to wild type in the presence of fluconazole.
Interestingly, although both ScRox1 and Rox1 contain homologous DNA binding
domains, the HMG DNA binding domain for ScRox1 is positioned at the N terminus,
while the DNA binding domain of Rox1 is at the C terminus (Fig. 2C). The ROX1 muta-
tions are nonsense mutations either early in the N-terminal portion or within the DNA
binding domain (Fig. 2C).
Loss-of-function mutations of ROX1 suppress fluconazole hypersusceptibility of
upc2AD strains. To confirm that the loss-of-function mutations identified in the upc2AD
fluconazole suppressor strains were responsible for this phenotype, we attempted to
make the corresponding double mutant deletion strains. In the case of ROX1, we were
able to generate the rox1D and rox1D upc2AD strains in the KKY2001 background; in
addition, we generated a rox1D mutation in a strain lacking PDR1, a transcription factor
that has a profound effect on fluconazole susceptibility. In the presence of fluconazole,
upc2AD and pdr1D cells have a significant growth defect relative to WT while the rox1D
strain is slightly less susceptible at high concentrations of fluconazole after 24 h but not
at 48 h (Fig. 3A). Deletion of ROX1 in the pdr1D background nearly restores WT growth at
the lowest concentrations of fluconazole after 48 h but has minimal effect on the
increased fluconazole susceptibility of the pdr1D mutant at higher concentrations. In con-
trast, deletion of ROX1 in the upc2AD mutant restores growth to a near-wild-type rate at
the lower concentrations of fluconazole and at longer incubation times. This strongly sup-
ports the conclusion that the loss-of-function mutations in ROX1 identified in the evolved
strains are responsible for the reduced fluconazole susceptibility relative to the upc2AD
FIG 3 Deletion of ROX1 suppresses fluconazole and hypoxia hypersusceptibility of upc2AD mutants.
(A) Tenfold dilution series of the indicated strains were spotted on YPD or YPD plates with the
indicated concentrations of fluconazole and incubated for 24 or 48 h at 30°C. (B) The indicated
strains were plated on YPD and incubated at 30°C in ambient air or in a GasPak to establish a low-
oxygen environment as described in Materials and Methods.
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parental strains. In addition, these data indicate that loss of Rox1 function is not a global
suppressor of fluconazole susceptibility since the mutation has minimal effects on WT or
pdr1D cells.
Despite multiple attempts to generate a cst6D upc2AD double mutant using both
standard recombination and CRISPR/Cas9 approaches, we were unable to do so. The
cst6D deletion mutant was generated as part of the large library of C. glabrata deletion
mutants. In addition, others have reported the construction of cst6D mutants in other
contexts (20). We obtained the cst6D strain from the library collection and determined
its susceptibility to fluconazole; in CLSI microdilution assays, it is less susceptible to flu-
conazole than the parental strain (MIC for cst6D strain, 16 mg/ml, versus WT, 4 mg/ml).
We elected to focus the rest of our characterization on the interaction between Rox1
and Upc2A since we were able to confirm that loss of function of ROX1 suppresses the
upc2AD fluconazole hypersusceptibility phenotype.
Upc2A is also required for C. glabrata to grow under hypoxic conditions (10, 11),
and ScRox1 was originally identified as a repressor of hypoxia-related genes during
growth under aerobic conditions (23). Accordingly, many genes repressed by ScRox1
during normoxia are also activated by ScUpc2. Therefore, we compared the growth of
the upc2AD rox1D strain to that of upc2AD and rox1D strains under low-oxygen condi-
tions (Fig. 3B). As expected, the upc2AD mutant grew poorly while the rox1D mutant
grew similar to the wild type. Consistent with its fluconazole phenotype, the rox1D
upc2AD mutant grew similarly to the wild type, indicating that ROX1 loss of function
suppressed both the fluconazole and hypoxia susceptibility of the upc2AD strain.
Deletion of ROX1 increases ergosterol content and alters the sterol profile of
upc2ADmutants. To gain insights into how rox1D affects the sterol content and distri-
bution (Fig. 4A) in the presence and absence of fluconazole, we used mass spectrome-
try to characterize the sterol profile of WT, upc2AD, rox1D, and rox1D upc2AD strains in
YPD medium with and without 8 mg/ml fluconazole. In the absence of fluconazole, WT,
rox1D, and upc2AD strains had statistically indistinguishable amounts of total cell er-
gosterol while the rox1D upc2AD strain had ;1.5-fold more ergosterol than the other
strains (Fig. 4B). In the presence of fluconazole concentrations that allowed the upc2AD
strian to grow, albeit at a reduced rate (Fig. S1), the rox1D strain had modestly increased
ergosterol while the ergosterol content of the upc2AD mutant was reduced slightly
(Fig. 4C). The rox1D upc2AD double mutant, in contrast, had nearly 50% more ergosterol
than the upc2AD deletion mutant and had statistically significantly increased ergosterol
content over that of WT.
We also determined the relative ratios of the different intermediate and alternative
pathway sterols for the mutants with and without fluconazole exposure. The ergosterol
biosynthesis intermediate (Fig. 4A) that is most altered in the upc2AD rox1D mutant in
both the presence (Fig. 4D) and absence of fluconazole is zymosterol (Table S1), a sub-
strate for the C24 methyltransferase enzyme Erg6. Zymosterol accumulates in both
rox1D and upc2AD rox1D strains in the absence of fluconazole (Table S1) but does so in
the double mutant only in the presence of fluconazole (Fig. 4D). These data suggest
that Erg6 activity is reduced in strains lacking ROX1 and particularly in fluconazole-
treated rox1D upc2AD mutants. Erg6 also catalyzes the conversion of lanosterol, the
substrate of Erg11, into eburicol, the first sterol in the alternate pathway (Fig. 4A).
Lanosterol is a minor component of total sterols in the absence of fluconazole (WT/
YPD: 1.28%, Table S1) but increases dramatically in fluconazole-treated cells (WT/FLC:
20%, Table S1) because the activity of Erg11 is inhibited. As shown in Fig. 4E, lanosterol
is further increased in fluconazole-treated rox1D upc2AD mutants relative to flucona-
zole-treated WT. Since ergosterol is not depleted in the rox1D upc2AD mutant, the
increase in lanosterol seems unlikely to be due to differences in Erg11 activity but
rather to reduced Erg6-mediated conversion of lanosterol to eburicol (Fig. 4A). Further
supporting this notion, eburicol is significantly reduced in fluconazole-treated rox1D
upc2AD cells relative to WT (Fig. 4F). These data strongly support the idea that the
combination of upc2AD and rox1Dmutations leads to reduced Erg6 activity in the pres-
ence of fluconazole.
C. glabrata Rox1 Negatively Regulates ERG Expression














































FIG 4 The rox1D upc2AD mutants have altered sterol profiles. (A) Schematic of the late portion of the ergosterol
biosynthesis pathway. (B and C) The content of ergosterol (mg/mg cell weight) was determined as described in Materials and
Methods from log-phase YPD cultures of the indicated strains without (B) and with (C) fluconazole (8 mg/ml). (D to I) The
percentage of the indicated sterols relative to total sterols for the indicated strains was determined for fluconazole-treated
(Continued on next page)
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Ultimately, the alternate pathway converts lanosterol to 14a methyl-ergosta-8,24
(28)-dien-3b , 6a-diol (Fig. 4A), which is toxic to cells and is thought to be part of the
mechanism by which azole drugs inhibit fungal growth (25). In rox1D upc2AD mutants
treated with fluconazole, the toxic dienol is reduced relative to upc2AD and WT strains
(Fig. 4G). In addition, the proportion of 14a methyl fecosterol, the immediate precursor
to 14a methyl-ergosta-8,24(28)-dien-3b , 6a-diol, is also increased in rox1D upc2AD
mutants treated with fluconazole (Fig. 4H). Erg3 catalyzes this conversion (Fig. 4A), and
the accumulation of 14a methyl fecosterol in the fluconazole-treated upc2AD rox1D
double mutant suggests that Erg3 activity may also be reduced in that strain.
In the ergosterol pathway, Erg3 also converts episterol to ergosta-5,7,24(28)-trienol.
Although episterol is elevated in the fluconazole-treated rox1D upc2AD mutant, the
variation between samples is too great to confidently conclude that it accumulates
(Table S1). The previous sterol in the pathway is fecosterol, and its levels are increased
5-fold in the fluconazole-treated rox1D upc2AD mutant relative to fluconazole-treated
wild type (Fig. 4I). Because Erg3 mediates the conversion of fecosterol to episterol, it is
likely that its reduced activity leads to the accumulation of fecosterol as well. Taken to-
gether, these data indicate that the rox1D upc2AD double mutant appears to have
both increased overall ergosterol and reduced accumulation of the toxic diol relative
to the upc2AD strain in the presence of fluconazole. The sterol profiles suggest that the
near-WT susceptibility of the upc2AD rox1D strain to fluconazole may be due to altera-
tions in the activity of Erg6 and Erg3. Since both Rox1 and Upc2A are transcriptional
regulators of ERG genes, it seems likely that the mechanism of this remodeling of the
rox1D upc2AD strain’s sterol composition is due, at least in part, to differential expres-
sion of genes such as ERG3 and ERG6.
ERG11 gene expression is maintained at WT levels in the rox1D upc2AD strain
while ERG3 and ERG6 expression is reduced in the presence of fluconazole. We
hypothesized that altered expression of ERG genes such as ERG3, ERG6, and ERG11
might be responsible for the changes in sterol content in rox1D upc2AD mutants
exposed to fluconazole. To test that hypothesis, we determined the expression of
ERG1-11&24 in WT, upc2AD, rox1D, and rox1D upc2AD strains in the presence and ab-
sence of fluconazole using quantitative reverse transcription-PCR (qRT-PCR) (Fig. 5A). A
notable feature of the effect of these mutations on ERG gene expression is that it varies
with the specific ERG gene. In the presence of fluconazole, the upc2AD mutant has the
most consistent reduction in ERG gene expression with all but ERG5 and ERG7 having
reduced expression relative to fluconazole-treated WT cells. This is as expected from
previously reported data.
In the absence of fluconazole, ERG11 expression is elevated 3.5-fold in the rox1D
upc2AD mutant relative to WT (Fig. 5A and B). Since this strain lacks Upc2A, the only
known regulator of ERG gene expression in Candida, the elevated expression of ERG11
indicates that at least one other positive transcriptional regulator must exist. This
increase in ERG11 expression correlates well with the increase in ergosterol content
observed for this strain when grown in YPD (Fig. 4B). In the presence of fluconazole
(Fig. 5A and B), ERG11 expression in the rox1D upc2AD strain is nearly identical to WT
but reduced somewhat relative to the untreated strain, indicating that loss of Upc2A
function has an effect on the expression of ERG11. Western blot analysis (Fig. 5C) con-
firmed the RNA levels as shown in Fig. 5B. Thus, the double mutant restores the expres-
sion of the fluconazole target Erg11 in the upc2AD background to a level similar to
that of the wild type, providing at least a partial explanation for the ability of rox1D de-
letion to suppress the upc2AD fluconazole hypersusceptibility.
FIG 4 Legend (Continued)
samples. (D) Zymosterol. (E) Lanosterol. (F) Eburicol. (G) 14a-Methyl-ergosta-diene-diol is a shortened name for 14a methyl-
ergosta-8,24(28)-dien-3b , 6a-diol. (H) 14-Methyl fecosterol. (I) Fecosterol. The bars indicate the means with standard errors of
the means. Statistical significance relative to wild type is indicated by an asterisk. Data were analyzed by analysis of variance
(ANOVA) followed by Student t tests with Bonferroni adjustment for individual comparisons with P , 0.05 indicating
statistical significance. The complete sterol data are provided in Table S1.
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Overall, 8 of the 11 ERG genes that we examined are expressed in the rox1D upc2AD
mutant at levels that correspond to $75% of WT in the presence of fluconazole
(Fig. 5A). Of these 8, ERG11, ERG2, and ERG3 are reduced by at least 2-fold in the fluco-
nazole-treated upc2AD mutant. Surprisingly, ERG6 is not significantly reduced in either
the rox1D or the upc2AD mutant in the presence of fluconazole (Fig. 5D). In the rox1D
upc2AD mutant, however, ERG6 expression is dramatically reduced, indicating that
there is a strong negative genetic interaction between upc2AD and rox1D mutations
with respect to ERG6 expression. As discussed above, the reduced expression of ERG6
in the fluconazole-treated rox1D upc2AD mutant is consistent with the sterol profiling
data indicating decreased flux through that enzyme.
The expression of ERG3 is also reduced in the fluconazole-treated rox1D upc2AD
mutant (Fig. 5A and E) and correlates with sterol profiling evidence of reduced flux
through that enzyme as well. ERG3 is upregulated in the rox1D mutant in the presence
FIG 5 Deletion of rox1D in the upc2AD mutant restores ERG11 expression to nearly wild-type levels in the presence of fluconazole.
(A) The expression of the indicated ERG genes in WT, rox1D, upc2AD, and upc2AD rox1D strains in the presence and absence of
fluconazole (8 mg/ml) was determined by quantitative RT-PCR and is normalized to WT and summarized in a heat map. (B) The
expression of ERG11 in the indicated strains. (C) Western blot of the indicated strains grown in YPD or YPD 1 8 mg/ml fluconazole for
4 h. (D) Expression of ERG6 in the indicated strains. (E) Expression of ERG3 in the indicated strains. The strains were incubated in YPD
or YPD 1 8 mg/ml fluconazole for 4 h. The bars are means from three biological replicates performed in technical triplicate. The error
bars indicate standard deviation, and Student’s t test was used to determine statistical significance. Statistical significance relative to
wild type is indicated by an asterisk.
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of fluconazole and downregulated in the upc2AD mutant (Fig. 5E). In contrast to
ERG11, however, the derepression of ERG3 in the rox1D mutant does not compensate
for its reduced expression in the upc2AD mutant, and indeed, its expression remains
reduced in the rox1D upc2AD mutant (Fig. 5E). This provides further support for the
conclusion that the relationship between Rox1 and Upc2A is more complex than a
repressor and activator of a shared set of genes. However, the wild-type levels of
ERG11 expression in the fluconazole-treated rox1D upc2AD mutant coupled with the
reduced expression of ERG3 and ERG6 provide a potential mechanism for the ability of
rox1D to suppress upc2AD fluconazole hypersusceptibility.
Transcriptional profiling of upc2AD, rox1D, and upc2AD rox1D strains. To char-
acterize the effect of the double mutant on genome-wide gene expression, we per-
formed transcriptome sequencing (RNA-Seq) on upc2AD, rox1D, and upc2AD rox1D
strains in the presence and absence of fluconazole. The processed data sets for all
strains and conditions are provided in Table S2. The trends for ERG gene expression
observed in our single-gene analysis were consistent with those found in the genome-
wide expression profiling. The role of ROX1 in C. glabrata gene expression has not previ-
ously been characterized. As discussed above, its role in the repression of hypoxia-related
genes during normoxia is well characterized in S. cerevisiae (15, 23). In log-phase growth
in YPD, 90 genes are upregulated by 2-fold with a corrected P value of#0.05 (Fig. 6A). As
shown in Fig. 6B, 5 genes involved in hypoxic response were upregulated, suggesting
that Rox1 function is conserved between C. glabrata and S. cerevisiae. Previously
reported transcriptional profiling indicated that ScRox1 suppresses cell wall-related
genes (23). Consistent with those findings, cell wall genes were enriched (GO term,
corrected P = 3.4  1024; Fig. 6C), further supporting conservation of function
between ScRox1 and Rox1.
In the presence of fluconazole, Rox1 would be expected to no longer repress genes
required for the cellular response to sterol depletion, and thus, those genes may not
be differentially regulated in the deletion mutant relative to WT. In the presence of flu-
conazole, 93 genes are upregulated in the rox1D mutant. Of the 93 genes, 48 remain
upregulated in the presence of fluconazole while 42 are no longer upregulated; the
latter set would be candidate genes that may be Rox1 regulated in the presence of
sterol stress. This set of genes is enriched for carbohydrate metabolic processes
(P = 7.7  1024) and the oxidation-reduction process (P = 3.1  1023), two classes of
genes also found to be Scrox1 dependent during sterol stress (23). The genes upreg-
ulated only in the presence of fluconazole were not enriched for any process or cel-
lular compartment by GO term analysis while those in common were enriched in
cell wall-related genes (P = 9.25  1026) and included TIR3, a cell wall gene impli-
cated in sterol uptake (11, 26).
The effect of the upc2AD mutation on gene expression in the presence and absence
of fluconazole has recently been reported by Vu et al. (27), and our results are consist-
ent with those data. We used our upc2AD strain data for comparison with the rox1D
upc2AD strain (Fig. 7A) in the presence of fluconazole to determine whether non-ERG
genes that were downregulated in the upc2AD strain were returned to WT levels of
expression by the deletion of ROX1. Nineteen of the 32 genes downregulated in the
fluconazole-treated upc2AD mutant were either equal to WT expression or upregulated
in the rox1D upc2AD mutant. As expected, this set of genes was enriched for ergosterol
biosynthesis genes (P = 5.8  1029). In addition, UMP biosynthesis genes (corrected
P = 8.8  1028) and oxidation-reduction genes (P = 2.8  1025) were enriched,
although it is difficult to connect these genes to fluconazole response. Thus, it appears
that loss of Rox1 function restores the expression of some Upc2A-dependent genes to
levels comparable to WT cells in the presence of fluconazole. Recently, the regulon for
Upc2A has been characterized using chromatin immunoprecipitation sequencing
(ChIP-seq) (27). Using these data, we asked what proportion of genes that are upregu-
lated in the rox1D upc2AD mutant relative to the upc2AD mutant are direct targets of
Upc2A. As shown in Fig. 7B, 23 of the 115 genes upregulated by deletion of ROX1 in
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the upc2AD background are direct targets of Upc2A. This observation further supports
the conclusion that Upc2A-independent pathways also regulate Upc2A targets in the
presence of fluconazole and that Rox1 must still play a repressive role in the presence
of fluconazole.
Relative to wild type in fluconazole, the rox1D upc2AD mutant has 157 genes that
are upregulated (Fig. 7C and D). Both upc2AD and rox1D mutants also have significant
numbers of genes upregulated in the presence of fluconazole, 159 and 93, respec-
tively. It seems likely that many of the genes that are upregulated in the fluconazole-
treated upc2AD strain are related to a compensatory response to the severe sterol
stress of those cells. Consistent with that hypothesis, 15 cell wall genes are upregulated
in the fluconazole-treated upc2AD cells (corrected P = 0.04). These include the cell wall
integrity pathway (CWIP) mitogen-activated protein kinase (MAPK) Slt2, a gene known
to be induced and activated by sterol stress (28), along with FKS2, the gene encoding a
catalytic subunit of 1,3-b-glucan synthase, which is a gene upregulated by activation
of Slt2. Of the 153 genes that are upregulated in the upc2AD mutant, only 40 (26%) are
among the 158 genes that are upregulated in the double mutant in the presence of
fluconazole (Fig. 7D). This set is no longer enriched for cell wall genes, and indeed,
FIG 6 Rox1 represses the expression of hypoxia and cell wall-related genes under normoxia. (A) Volcano plot
comparing the expression of genes in the rox1D mutant to that in the WT in log-phase cultures incubated for
4 h in YPD at 30°C. Red indicates genes that are changed by 62-fold with an adjusted P value of ,0.05. (B
and C) The expression of hypoxia-related (B) and cell wall-related (C) genes in rox1D mutant relative to WT
under conditions indicated above. GPI, glycophosphatidylinositol.
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none of the 15 cell wall genes remain upregulated. These observations are consistent
with the hypothesis that the large set of genes upregulated in the upc2AD strain repre-
sents an exaggerated compensatory response to sterol stress that is then largely elimi-
nated by the deletion of ROX1.
Overall, our transcriptional profiling supports the conclusion that Rox1 function is
reasonably well conserved between S. cerevisiae and C. glabrata. Deletion of Rox1 sup-
presses the upc2AD fluconazole hypersusceptibility phenotype, at least in part, by der-
epressing ERG gene expression through a Upc2A-independent pathway. Finally, fluco-
nazole-treated upc2AD cells display a compensatory transcriptional response that is no
longer induced in the fluconazole-treated rox1D upc2AD double mutant.
DISCUSSION
The ergosterol biosynthesis pathway is not only an essential component of fungal
membrane biology but also the target of two of the three classes of drugs that are
used to treat human fungal infections. Despite its centrality to fungal biology and anti-
fungal drug therapy, our models for the regulation of ergosterol biosynthesis are rela-
tively limited, particularly in the case of pathogenic fungi (13). In general, current
understanding of the transcriptional regulation of ERG gene expression is limited
almost entirely to the role of SREB transcription factors or functionally homologous, Zn
FIG 7 Transcriptional profile of the rox1D upc2AD mutant relative to WT and to the single mutant
strains in the presence of fluconazole. The strains were incubated in YPD 1 8 mg/ml fluconazole for
4 h. (A) Volcano plot comparing rox1D upc2AD to upc2AD strains. Red indicates genes that are
changed by 62-fold with a corrected P value of ,0.05. ERG genes meeting these criteria are labeled.
(B) Venn diagram of genes upregulated in the rox1D upc2AD mutant relative to WT in the presence
of fluconazole compared to Upc2A targets identified by ChIP-seq (27). (C) Comparison of the rox1D
upc2AD mutant to WT in the presence of fluconazole. (D) Venn diagram of genes upregulated in
fluconazole-treated rox1D, upc2AD, and rox1D upc2AD mutants.
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cluster transcription factors such as Upc2A (14). Although many ERG genes are known
to be essential, none of the TFs that regulate their expression are essential, indicating
that additional factors are likely to contribute to the regulation of ERG genes. In addi-
tion, overexpression experiments in S. cerevisiae have shown that inappropriately high
expression of ERG genes reduces fitness, likely due to the fact that sterols can be toxic
to the cell (29). As such, it seemed likely that negative regulators of sterol biosynthesis
may be required to maintain sterol homeostasis. Our screen was designed to identify
either gain-of-function mutants in positive regulators of ERG gene expression or loss-
of-function mutants in negative regulators and yielded two negative regulators of ERG
gene expression: Rox1 and potentially Cst6.
Based on previous work regarding the roles of ScRox1 and ScUpc2/Ecm22 in the
regulation of hypoxia and sterol stress, the ability of rox1D to suppress the upc2AD
phenotype is somewhat unexpected. Specifically, in S. cerevisiae, ScRox1 represses
many genes that are activated by ScUpc2, and thus, loss of the Rox1 repressor should
require the presence of the cognate activator for shared genes to be expressed (23). In
the presence of fluconazole, the deletion of ROX1 in the upc2AD strain leads to normal-
ization of some, but not all, ERG gene expression and increased overall levels of ergos-
terol relative to WT C. glabrata cells. Accordingly, there must be a transcription factor
in addition to Upc2A that is able to activate the expression of at least some ERG genes
in the presence of fluconazole; otherwise, loss of the repressor Rox1 would not be able
to restore growth during sterol stress because UPC2A was deleted in the parental
strains used in the screen. This factor also must be sufficient to restore growth under
hypoxic conditions to upc2AD mutants because the rox1D mutation suppresses the
hypersensitivity of the upc2ADmutant to those conditions.
Upc2A is currently the only factor that has been directly implicated in the regulation
of ERG genes in C. glabrata (9–14). Although Upc2B would seem a logical candidate for
this factor, it has not been shown to play a role in the regulation of ERG genes (10). In
the fluconazole-treated upc2AD rox1D mutants, UPC2B expression is modestly reduced
(see Table S2 in the supplemental material). This is consistent with previously pub-
lished data indicating that Upc2A is required for induction of UPC2B expression (10).
We cannot completely rule out the possibility that Upc2B contributes to the regulation
of ERG gene expression in the absence of UPC2A, but the current data seem more con-
sistent with an alternative explanation.
A second candidate factor is Hap1 which, based on the large-scale genetic phenotyp-
ing project, is required for WT growth in fluconazole (17). HAP1 is upregulated in the
rox1D mutant in the absence of fluconazole and is expressed near WT levels in the pres-
ence of fluconazole in the upc2AD rox1D double mutant (Table S2). Hap1 is also involved
in the expression of ERG genes under unstressed conditions in S. cerevisiae (30). Certainly,
other factors with less obvious effects on fluconazole stress could also be involved.
Another question raised by our observations is, why is the putative missing ERG
gene regulating factor not activated in the presence of fluconazole to compensate for
the upc2AD mutation? The genetic interaction of upc2AD and rox1D implies that the
presence of Rox1 prevents this factor from positively regulating ERG gene expression
in the absence of Upc2A. The data also suggest that Rox1 may still repress the expres-
sion of some genes during treatment with fluconazole or under low-oxygen condi-
tions. However, the only transcription factor that is upregulated in the rox1D upc2AD
mutant is Stb5, which has been shown as a negative regulator of azole susceptibility
by decreasing expression of CDR1 and other efflux pumps (31). Another possibility is
that Upc2A may be needed to fully displace Rox1 from promoters and Rox1, in turn,
may directly interfere with the binding of this other positive activator to ERG gene pro-
moters. Additional work will be needed to identify the missing positive regulator and
understand the mechanism for the interactions between the positive and negative reg-
ulators of ergosterol biosynthesis.
The biochemical mechanism by which the rox1D mutation suppresses upc2AD flu-
conazole hypersusceptibility is by restoring ERG11 and other ERG genes to wild-type or
Ollinger et al.














































nearly wild-type levels in the presence of fluconazole and, thereby, leading to
increased ergosterol content in rox1D upc2AD cells relative to upc2AD cells. The sterol
profile of the fluconazole-treated double mutant differs from WT, indicating that nor-
mal flux through the ergosterol pathway has not been reestablished. Specifically, ster-
ols that are dependent on Erg3 and Erg6 are reduced while the sterols that serve as
the Erg3 and Erg6 substrates are increased. This correlates with reduced expression of
the ERG3 and ERG6 genes in the double mutant. The fact that the double mutant has
ERG11 expression restored to WT levels but not ERG3 and ERG6 further emphasizes the
complexity of ergosterol biosynthesis gene regulation and that Upc2A and Rox1 are
not simply on/off switches for a common set of genes.
Furthermore, this apparent reduction in Erg3 and Erg6 leads to a reduction in the
toxic sterol 14a methyl-ergosta-8,24(28)-dien-3b , 6a-diol, which accumulates in cells
treated with the Erg11-inhibiting azoles (25). Thus, the rox1D upc2AD strain has both
an increase in ergosterol and a decrease in the toxic sterol relative to upc2AD and wild-
type cells. This not only provides a mechanism for the restoration of wild-type azole
susceptibility through deletion of ROX1 in the upc2AD mutant but also indicates that
changes in the relative expression of ERG genes can lead to profound changes in azole
susceptibility. In principle, these data suggest that single nucleotide polymorphisms
(SNPs) in the promoter regions of ERG genes or epigenetic alterations in gene expres-
sion could lead to changes in azole susceptibility without any change to protein cod-
ing sequences.
Lastly, we consider the implications of our findings in C. glabrata for C. albicans, which,
as noted in this section, has a number of distinctions with respect to the genetic regula-
tion of fluconazole susceptibility. Most notably, the Rox1 homolog in C. albicans is Rfg1,
and although it is an HMG class repressor, it has no role in the suppression of hypoxia
genes. Instead, it represses filamentation (32, 33). Although a Upc2A homolog is present
and has been shown to function very similarly, there are no Upc2B/ScEcm33 homologs in
C. albicans. Taken together, our data provide strong evidence for the conclusion that,
although the ergosterol biosynthesis pathway is highly conserved among pathogenic
and model yeasts, significant changes have occurred in terms of its transcriptional regula-
tion. A more detailed understanding of these distinctions may provide additional insights
into the possible mechanisms of resistance to inhibitors of ergosterol biosynthesis.
In summary, our genetic suppressor study provides new insights into the regulation
of ergosterol biosynthesis and fluconazole response pathways in C. glabrata. These
data highlight the complex nature of the transcriptional pathways that maintain ergos-
terol homeostasis during normal growth and under sterol stress. Future studies will fur-
ther explore mechanisms by which the putative Rox1 suppressor pathway is regulated
and how Cst6 affects ergosterol biosynthesis in C. glabrata.
MATERIALS ANDMETHODS
Media, reagents, and general methods. Yeast-peptone-dextrose (YPD) and synthetic complete me-
dium (SCM) with amino acid dropout/supplements were prepared using standard recipes (34) for both
liquid and plate (2% agar)-based media. Strains were streaked from frozen stocks onto YPD plates and
incubated at 30°C. For all experiments, strains were precultured in liquid medium with shaking at 30°C
overnight. Fluconazole was obtained as a powder from Sigma.
Strain and plasmid construction. The parental upc2AD strain for the laboratory evolution experi-
ment was constructed in the BG2 background (17) as described in the work of Vu et al. using the recycla-
ble nourseothricin (NAT) cassette flanked by 1 kb of homology to the upstream and downstream regions
of UPC2A (18). Correct integration was confirmed by PCR as was the absence of the UPC2A open reading
frame (ORF). The rox1D upc2AD mutant was constructed in a similar manner in the KK2001 background
by deleting the ROX1 coding region from the previously reported upc2AD ERG11-hemagglutinin (HA)
strain (27).
C. glabrata transformation. Transformations of C. glabrata were performed using the lithium ace-
tate method (18). After heat shock, cells were grown overnight at 30°C at 200 rpm for drug selection.
Overnight cultures were spun down and plated on YPD plates supplemented with 100 mg/ml of nour-
seothricin (NAT) (Jena Bioscience, Jena, Germany). Colonies were purified by plating on YPD plates con-
taining 200mg/ml NAT.
Experimental evolution of suppressors of upc2AD fluconazole hypersusceptibility. Three inde-
pendent colonies of the upc2AD mutant in the His-BG2 background were precultured overnight in YPD.
The three cultures were used to inoculate three separate 96-well plates at 1,000 CFU/well in YPD
C. glabrata Rox1 Negatively Regulates ERG Expression














































containing 0.25 mg/ml fluconazole (1/4 MIC for this strain). The plates were incubated at 30°C until the
wells were saturated. The cultures were serially passaged by transferring 2 ml of each well to a fresh
plate containing 2 the fluconazole concentration as the previous plate up to a final concentration of
64 mg/ml. Surviving lineages were plated on YPD, and random colonies from each were serially streaked
on YPD without fluconazole. The ability of the strains to grow with 64 mg/ml fluconazole was retested.
From this experiment, 12 independent strains derived from the upc2AD mutant with the ability to grow
with 64 mg/ml were isolated: the table in Fig. 2A shows the names of the resistant strains. The genomes
of the strains were sequenced using Illumina at the University of Iowa Genomics Core. The genomes
were assembled, and SNPs were called using the Lasergene platform.
Spot dilution assay. Strains were grown overnight at 30°C and 200 rpm in liquid YPD, SCM, or SCM
without methionine and cysteine. For YPD and YPD 1 fluconazole, the strains were diluted to an optical
density at 600 nm (OD600) of 1 and plated with 10-fold serial dilutions. Plates were incubated at 30°C or
37°C for 1 to 3 days before photographing them.
Hypoxia growth assay. Cells were grown in liquid YPD overnight at 30°C and 200 rpm and diluted
to an OD of 1. Cells were plated on YPD and serially diluted 10-fold for spot dilutions. Plates were sealed
in an BD GasPak EZ anaerobe gas generating pouch system with indicator and placed in a 30°C incuba-
tor or placed directly in an incubator. Plates were captured after 48 h.
Western blot analysis. Strains were incubated in YPD or with YPD in fluconazole for 4 h. Proteins
were extracted as previously described (27), resuspended in 120 ml of urea-SDS sample buffer (8 M urea,
5% SDS, 1% 2-mercaptoethanol, 40 mM Tris-HCl, pH 8.0, bromophenol blue), and incubated at 37°C for
3 h by occasional vortexing. Aliquots of 12 ml were resolved on a precast ExpressPlus 4 to 12% gradient
gel (GenScript catalog no. M41212). Proteins were electroblotted to an nitrocellulose membrane,
blocked with 5% nonfat dry milk. Membrane was probed with polyclonal anti-Cdr1 antibody (27) in the
final dilution of 1:1,000 overnight at 4°C and with 12G10 anti-alpha-tubulin monoclonal antibody
(Developmental Studies Hybridoma Bank at the University of Iowa) in the final dilution of 1:5,000 for 15
min at room temperature. Secondary Li-Cor antibodies IRD dye 680RD goat anti-rabbit (catalog no. 926-
68021) and IRD dye 800LT goat anti-mouse (catalog no. 926-32210) were used in the final dilution of
1:10,000. A Li-Cor infrared imaging system (Li-Cor; application software version 3.0) was used to detect
the signal. The data represent results of two biologically independent experiments.
Sterol profiling.Overnight cultures from single colonies of C. glabrata strains were used to inoculate
20 ml YPD (starting OD600 of 0.20) in the absence (dimethyl sulfoxide [DMSO] control, 1% [vol/vol]) or
presence of 8 mg/ml fluconazole (stock prepared in DMSO; final concentration, 1% [vol/vol] DMSO).
Cultures were grown at 30°C for 16 h at 180 rpm. Cells were then pelleted and washed with double-dis-
tilled water (ddH2O) before splitting each sample for sterol extraction and dry weight determination.
Sterols were extracted and derivatized as previously described (35). An internal standard of 5 mg of cho-
lesterol was added to each sample, and lipids were saponified using alcoholic KOH and nonsaponifiable
lipids extracted with hexane. Samples were dried in a vacuum centrifuge and were derivatized by the
addition of 0.1 ml N,O-bis(trimethylsilyl)trifluoroacetamide/trimethylchlorosilane (99:1; Sigma) and
0.3 ml anhydrous pyridine (Sigma) and heating at 80°C for 2 h. Trimethylsilyl-derivatized sterols were an-
alyzed and identified using gas chromatography-mass spectrometry (GC-MS) (Thermo 1300 GC coupled
to a Thermo ISQ mass spectrometer; Thermo Scientific) and Xcalibur software (Thermo Scientific). The
retention times and fragmentation spectra for known standards were used to identify sterols. Integrated
peak areas were determined to calculate the percentage of total sterols. Ergosterol quantities were
determined using standard curves of peak areas of known quantities of cholesterol and ergosterol.
Sterol composition and ergosterol quantities were calculated as the mean from three replicates. The sta-
tistical significance of the differences between strains was determined using the means and standard
errors of the means and Student’s t test with P , 0.05 indicating statistical significance. The complete
sterol data and summary are provided in Table S1 in the supplemental material.
Transcriptional analysis by qPCR. Strains were incubated overnight in liquid YPD at 30°C at
200 rpm, back-diluted into fresh YPD, and grown to mid-log phase. Cells were harvested at mid-log
phase and resuspended into fresh YPD or YPD with 8 mg/ml of fluconazole. Cultures were incubated for
4 h and harvested, and total RNA was isolated with the MasterPure yeast RNA purification kit. The RNA
was reverse transcribed using the iScript cDNA synthesis kit (170-8891; Bio-Rad), and quantitative
reverse transcription-PCR (qPCR) was performed using IQ SyberGreen supermix (170-8882; Bio-Rad).
ACT1 expression was used as the normalization standard, and relative expression between strains and
conditions was determined using the cycle threshold (DDCT) method. Experiments were performed in bi-
ological duplicate with technical triplicates, and the statistical significance was determined using
Student’s t test with a significance limit of P , 0.05.
RNA sequencing methods. The strains were grown with and without fluconazole as described for
single-gene expression analysis by qRT-PCR. RNA sequencing was performed using Illumina MiSeq for
stranded mRNA. Libraries were prepared with paired-end adapters using Illumina chemistries per manu-
facturer’s instructions, and sequencing of libraries was performed with read lengths of approximately
150 bp with at least 50 million reads per sample. RNA sequencing reads were imported into CLC
Genomics Workbench 20.0. Sequences were trimmed and aligned to reference sequence (https://www
.ncbi.nlm.nih.gov/assembly/GCF_000002545.3) ASM254v2_genomic-1 with paired reads counted as one.
Mismatch, insertion, and deletion costs were set to CLC default parameters. Differential expression anal-
ysis for whole-transcriptome RNA-Seq was performed using CLC Genomics Workbench. The Wald test
was used in all group pairs against the indicated control group. Statistics were based on the fit of a gen-
eralized linear model with a negative binomial distribution. C. glabrata gene annotations were obtained
from the Candida Genome Database. The fold changes and corrected P values for all genes and all
Ollinger et al.














































conditions are provided in Table S2. GO term analysis was performed using the FungiDB website using
Benjamini-Hochberg-corrected P values of ,0.05 to identify significantly enriched gene sets.
Data availability. Study data have been deposited in the NCBI Gene Expression Omnibus under
accession number GSE191145.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
FIG S1, TIF file, 0.2 MB.
TABLE S1, XLSX file, 0.1 MB.
TABLE S2, XLSX file, 1.9 MB.
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